Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director David A. Socks Sells 12,835 Shares
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director David A. Socks sold 12,835 shares of the business’s stock in a transaction on Monday, January 11th. The stock was sold at an average price of $34.92, for a total transaction of $448,198.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of NASDAQ:PHAT traded down $0.06 on Wednesday, hitting $36.25. The company had a trading volume of 65,870 shares, compared to its average volume of 122,021. The company has a current ratio of 18.76, a quick ratio of 18.76 and a debt-to-equity ratio of 0.24. The stock has a 50 day moving average price of $40.01 and a 200 day moving average price of $37.28. Phathom Pharmaceuticals, Inc. has a 1-year low of $22.06 and a 1-year high of $64.54. The stock has a market cap of $1.05 billion and a price-to-earnings ratio of -2.59.
Phathom Pharmaceuticals (NASDAQ:PHAT) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($1.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.35). Sell-side analysts anticipate that Phathom Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on PHAT. Zacks Investment Research upgraded shares of Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 5th. BidaskClub upgraded shares of Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 7th. Needham & Company LLC upped their price objective on shares of Phathom Pharmaceuticals from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, December 15th. Finally, ValuEngine upgraded shares of Phathom Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Phathom Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $42.67.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Recommended Story: Capital Gains
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.